中国科普网突袭癌症的智能之箭ChatGPT点燃希望之光

《绝命毒师》剧照

经典靶点的奠基人到中国创业，会带来哪些改变？

前不久，一家名为赛得康的生物技术公司获得种子轮投资的消息，在医药行业媒体来了一轮“轰炸”。除了创业者之一宾夕法尼亚大学副教授张洪涛博士作为知名科普作家的感召力，其合伙人也非常值得关注——Mark Greene教授是肿瘤治疗经典靶点（HER2）治疗的奠基人。

是的，这个对大多数中国人来说很陌生的人名和生僻的字母组合，曾经突破乳腺癌治疗的瓶颈，给至少20%的患者带来活下来的希望。如今他的学生、同为该领域顶尖学者的张洪涛教授带着技术平台归国创业，专注于多特异性融合蛋白药物研发，让行业对这个科学家亲自下场实现科研成果转化的明星团队充满期待。

而这家公司的落地实际上也预示着全球第四波新药研发浪潮，正在中国达到新的高度。

两位科学家在中国创业影响几何？“第四波新药研发浪潮”对中国来说意味着什么？与之前的浪潮相比，中国的地位正在发生什么样的变化？在它的影响下，新药研发将走向何方？

从癌基因到靶向治疗

1981年，当Robert Weinberg实验室发现大鼠癌基因“neu”时，该研究揭示了一个关键机制：当这类基因发生突变时，它们可以导致癌症发展。这一发现开启了寻找并针对这些突变进行靶向疗法之门，并由此推动了HER2/neu靶向治疗领域的一系列进展。

1998年，当单克隆抗体赫赛汀获得美国FDA批准后，它成功打开了实体肿瘤对于单抗药物使用的大门，从而激励了整个生物科技行业采取更多创新策略以解决这一挑战。

随着时间推移，这种方法已经成为标准化的一部分。在2010年代中期之后，更先进和高效率的小分子或抗体-小分子的复杂结合形式开始出现，如ADCs（抗体偶联小分子），它们通过精确定位目标细胞表面的蛋白质，而不会被其他细胞吸收，使其更加有效且安全。此外，还有CAR-T（可重编程T细胞）疗法，它利用免疫系统自然杀伤能力，对恶性肿瘤进行精确打击，为患者提供全新的治愈机会。

尽管如此，与HER2类似，有许多需要打破当前局限性的其他重要靶点存在。例如，大量研究集中于开发能够同时识别多个病理标志物或抑制多条信号通路的小分子，以及利用这种方式设计出具有更强针对性和耐用性的疗法。这些努力旨在通过提高特异性、减少副作用以及扩大适应范围，以提升整个人群健康水平。

然而，这并不代表我们就要放弃现有的成果，而是在继续前行的时候，不断探索新的途径。正因为这样，我们才能真正迈入一个全新的时代，即使面临未知，也能勇敢地迈出第一步，因为每一步都可能开辟出一片未知天地。而现在，就在这样的背景下，我们迎来了第四波新药开发浪潮，将如何引领我们走向未来呢？

AbZed Protein Platform Technology: The Key to Unlocking the Next Generation of Cancer Treatments

The AbZed protein platform technology, developed by Zhang Hongtao and his team at RaceForLife, represents a significant breakthrough in cancer treatment. This innovative approach combines multiple proteins to create a single, highly effective therapeutic agent that can target specific cancer cells while minimizing harm to healthy tissues.

The AbZed platform has already shown promising results in preclinical studies, demonstrating improved efficacy and reduced toxicity compared to traditional treatments. Its versatility allows it to be adapted for use against various types of cancer, making it an exciting prospect for the future of personalized medicine.

As China continues to play an increasingly important role in the global pharmaceutical industry, innovations like the AbZed platform have the potential to drive further advancements in cancer research and treatment. With its cutting-edge technology and commitment to improving patient outcomes, RaceForLife is poised to make a meaningful impact on the lives of those affected by this devastating disease.

A New Era in Cancer Treatment: The Rise of Multitargeting Therapies

In recent years, there has been a growing interest in developing multitargeting therapies that can address multiple aspects of cancer biology simultaneously. These therapies aim to disrupt complex signaling pathways and inhibit key molecular targets involved in tumor growth and progression.

One example is ADCs (antibody-drug conjugates), which combine antibodies with potent cytotoxins or small molecules that specifically bind to tumor cells. This targeted approach enables more precise delivery of therapeutic agents directly into tumors while minimizing systemic side effects.

Another emerging area is CAR-T cell therapy, which harnesses the power of immune cells engineered with chimeric antigen receptors (CARs) capable of recognizing specific antigens on tumor cells. By exploiting these receptors' natural ability to recognize foreign substances within our bodies—such as viruses or bacteria—these modified T-cells can identify and destroy even hard-to-reach cancers without causing harm elsewhere.

These new technologies represent major strides forward towards more effective treatments for diverse types